Eli Lilly and Company (NYSE:LLY) Stock Price Target Raised at Royal Bank Of Canada

Eli Lilly and Company (NYSE:LLY) had its target price raised by analysts at Royal Bank Of Canada from $1,500.00 to $1,600.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price points to a potential upside of 12.54% from the stock’s current price.

Several other analysts have also recently weighed in on LLY. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Morgan Stanley increased their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a research report on Tuesday, September 15th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,374.46.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $47.99 during trading on Friday, hitting $1,421.69. The company had a trading volume of 1,916,131 shares, compared to its average volume of 2,927,632. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The stock has a market capitalization of $1.34 trillion, a price-to-earnings ratio of 47.67, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The stock’s 50-day moving average is $1,194.34 and its two-hundred day moving average is $1,090.89.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $7.02 EPS. As a group, analysts predict that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp lifted its stake in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after acquiring an additional 400,538 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted earnings per share of $7.48 exceeded analyst expectations. Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion. Reuters: Eli Lilly lifts revenue outlook
• Positive Sentiment: Mounjaro sales climbed 65% to $10.7 billion and Zepbound sales increased 49% to $5.35 billion. Combined tirzepatide sales surpassed $16 billion, reinforcing Lilly’s leadership in the rapidly expanding GLP-1 diabetes and weight-loss market. Pharmaceutical Technology: Eli Lilly’s tirzepatide outperforms
• Positive Sentiment: Management highlighted expanding Medicare access, rising demand from middle-income consumers and encouraging traction for Foundayo. Positive Phase 3 results for experimental obesity and diabetes drug retatrutide also strengthened expectations for Lilly’s future pipeline and increased competitive pressure on Novo Nordisk. Zacks: LLY Q3 earnings call highlights
• Neutral Sentiment: Lilly’s pipeline is broadening beyond GLP-1 therapies, with cancer, immunology and neuroscience products viewed as potential additional growth drivers. However, the stock’s strong rally has raised the performance bar and leaves investors focused on whether growth can remain strong at its current valuation. Yahoo Finance: Cancer drugs as future growth drivers
• Negative Sentiment: Realized prices fell about 15%, although a 53% volume increase more than offset the decline. Results also benefited from roughly $900 million in favorable items, while acquisition-related charges reduced earnings. Potential employer cutbacks in weight-loss-drug coverage and ongoing pricing pressure remain risks. Motley Fool: Eli Lilly sells more at lower prices

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.